Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis.
- G. Van Assche, A. Dignass, +11 authors E. Stange
- Medicine
- Journal of Crohn's & colitis
- 1 March 2006
Crohn's disease is a lifelong disease arising from an interaction between genetic and environmental factors, but observed predominantly in developed countries of the world. The precise aetiology is… Expand
Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.
It has recently been shown that repeated large-volume paracentesis associated with intravenous albumin infusion is a rapid, effective, and safe therapy of ascites in cirrhosis. To investigate whether… Expand
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.
- G. Van Assche, A. Dignass, +15 authors J. Lindsay
- Medicine
- Journal of Crohn's & colitis
- 1 February 2013
### 8.1 General
Proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the procedure of choice for most patients with ulcerative colitis (UC) requiring colectomy.1 Pouchitis is a non-specific… Expand
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
- W. Sandborn, C. Su, J. Panés
- Medicine
- The New England journal of medicine
- 2017
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
- W. Sandborn, S. Ghosh, +4 authors W. Niezychowski
- Medicine
- The New England journal of medicine
- 15 August 2012
BACKGROUND
Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective. One additional treatment may be tofacitinib (CP-690,550), an… Expand
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- S. Vermeire, S. O'Byrne, +22 authors P. Rutgeerts
- Medicine
- The Lancet
- 26 July 2014
BACKGROUND
Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit of the heterodimeric integrins α4β7 and αEβ7. We aimed to assess etrolizumab in patients with… Expand
Neutrophil Infiltration Increases Matrix Metalloproteinase-9 in the Ischemic Brain after Occlusion/Reperfusion of the Middle Cerebral Artery in Rats
- C. Justicia, J. Panés, +4 authors A. M. Planas
- Medicine
- Journal of cerebral blood flow and metabolism…
- 1 December 2003
Matrix metalloproteinase-9 (MMP-9) activity increases in the brain during the first day after focal ischemia and might be involved in the pathogenesis of tissue damage. We previously showed MMP-9 in… Expand
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- J. Gisbert, J. Panés
- Medicine
- The American Journal of Gastroenterology
- 27 January 2009
OBJECTIVES:To review the frequency with which infliximabloses its effect and dose “intensification” is required for Crohn's disease treatment.METHODS:Bibliographical searches were performed in… Expand
Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease.
- J. Panés, D. Granger
- Medicine
- Gastroenterology
- 1 May 1998
Leukocyte-endothelial cell adhesion is now recognized to represent an early and rate-limiting step in the leukocyte infiltration and accompanying tissue injury that is associated with acute and… Expand
Leukocyte‐endothelial cell adhesion: avenues for therapeutic intervention
- J. Panés, M. Perry, D. Granger
- Biology, Medicine
- British journal of pharmacology
- 1 February 1999
British Journal of Pharmacology (1999) 126, 537–550; doi:10.1038/sj.bjp.0702328